View Online / Journal Homepage / Table of Contents for this issue

RSC Advances
Cite this: RSC Advances, 2012, 2, 46124615 www.rsc.org/advances

Dynamic Article Links

COMMUNICATION

Synthesis and cytotoxic activities of novel hybrid compounds of imidazole scaffold-based 2-substituted benzofurans{
Wen-Jian Song, Xiao-Dong Yang,* Xiang-Hui Zeng, Xiao-Liang Xu, Gao-Lan Zhang and Hong-Bin Zhang*
Downloaded on 13 June 2012 Published on 27 March 2012 on http://pubs.rsc.org | doi:10.1039/C2RA20376F

Received 29th February 2012, Accepted 25th March 2012 DOI: 10.1039/c2ra20376f

A series of novel hybrid compounds between 2-substituted benzofuran and imidazole have been prepared and evaluated in vitro against a panel of human tumor cell lines. The results show that the hybrid compounds were more selective towards an ovarian carcinoma cell line (Skov-3) and suggest that hybrid compounds bearing 2-substituted benzofuran and benzimidazole moieties, as well as imidazolium salts, were vital for modulating cytotoxic activity. The 2-substituted benzofuran imidazole hybrids 24 and 8 can serve as valuable leads for further structural modifications. Cancer is a major burden of disease worldwide and is the leading cause of human mortality exceeded only by cardiovascular diseases.1 Therefore, development of new anticancer drugs and more effective treatment strategies for cancer are of the utmost importance.2 Natural products represent a significant source of inspiration for the design of structural analogues with improved pharmacological profiles in medicinal chemistry.3 Naturally occurring substituted benzofurans are an important class of biologically active oxygencontaining heterocycles. Natural products possessing the 2-substituted benzofuran moiety exhibit a broad range of biological and pharmacological activities such as antimicrobial, antiviral, antioxidant, antifungal, antiproliferative, anti-inflamanatory, antifeedant, anti-HIV and antiplatelet activities.4 Recently, naturally occurring benzofurans have been identified to possess anti-tumor activity.5 As exemplified in Scheme 1, 1-(6-hydroxy-2-isopropenyl-1-benzofuran5-yl)-1-ethanone6 and calophione A7 are also 2-substituted benzofuran derived compounds exhibiting potent cytotoxic activities against human breast cancer cells and colon cancer cells.6,7 Imidazole and its derivatives have attracted considerable interest in recent years for their versatile properties in chemistry and pharmacology. Biological activities of imidazole derivatives have been reported to include antimicrobial and antifungal, antimuscarinic, thromboxane synthetase inhibition, antiinflamatory, antiarrhythmic, and plasmid DNA cleavage activities,8 especially antitumor activity.9 For example, two new imidazolium halides
Key Laboratory of Medicinal Chemistry for Natural Resource (Yunnan University), Ministry of Education, School of Chemical Science and Technology, Yunnan University, Kunming, 650091, P. R. China. E-mail: zhanghbyd@gmail.com or xdyang@ynu.edu.cn; Fax: +86-871-5035538; Tel: +86-871-5031119 { Electronic supplementary information (ESI) available: scan spectral data of the novel hybrid compounds. See DOI: 10.1039/c2ra20376f.

(Scheme 1), Lepidiline A and Lepidiline B, isolated from the roots of Lepidium meyenii, showed potent cytotoxic activity against human cancer cell lines.10 Recently, we have reported the synthesis of a series of novel hybrid compounds of imidazole moieties such as NMIB (Scheme 1) and their potential anti-tumor activity.11 Molecular hybridization as a drug discovery strategy involves the rational design of new chemical entities by the fusion of two drugs, both active compounds and/or pharmacophoric units recognized and derived from known bioactive molecules.12 Considering the anticancer activities of naturally occurring 2-substituted benzofurans as well as the potent cytotoxic activities of natural and synthetic imidazole derivatives, we were interested in synthesizing a number of new hybrid compounds bearing 2-substituted benzofuran and imidazole moieties (Scheme 1). Although benzofurantriazole hybrid molecules through a heptyloxybenzene chain were synthesized and found to exhibit CYP26A1 inhibitory activity by Simons,13 to the best of our knowledge, no reports concerning anti-tumor activity for hybrid compounds between 2-substituted benzofuran and imidazole have been reported. In the present research, we have designed and synthesized a series of novel hybrid compounds of imidazole scaffold-based 2-substituted benzofurans. The purpose of this study was to investigate the antitumor activity of benzofuranimidazole hybrids, with the ultimate aim of developing novel potent anti-tumor agents. As shown in Scheme 2, substituted salicylaldehydes (1) were condensed with ethyl bromoacetate to afford benzofuran-2-carboxylate compounds (2, 7581% yields).14 The benzofuran 2-carboxylate compounds 2 were reduced with LiAlH4 to the respective benzofuran 2-methanol compounds (3, 7089% yields).15 Subsequently, the benzofuran 2-methanol compounds (3) were transformed via the mesylate to the respective fifteen 2-substituted benzofuranimidazole hybrids (418) with various substituted imidazoles by refluxing under toluene with 5483% yields (two steps).16 Finally, six benzofuranbased imidazolium salts (1924) were prepared with excellent yields by reaction of 2-substituted benzofuranimidazole hybrids with the corresponding alkyl bromides by refluxing under toluene (7592% yields).17 The structures of hybrid compounds are shown in Table 1. The cytotoxic potential of all newly synthesized hybrid compounds was evaluated in vitro against a panel of human tumor cell lines according to procedures described in the literature.18 The panel consisted of ovarian carcinoma (Skov-3), myeloid leukaemia (HL-60), and breast carcinoma (MCF-7). Cisplatin (DDP) was used
This journal is The Royal Society of Chemistry 2012

4612 | RSC Adv., 2012, 2, 46124615

View Online

Downloaded on 13 June 2012 Published on 27 March 2012 on http://pubs.rsc.org | doi:10.1039/C2RA20376F

Scheme 1 Design of novel hybrid compounds.

Scheme 2 Synthesis of hybrid compounds 421.

as the reference drug. The results are summarized in Table 1 (IC50 value, defined as the concentrations corresponding to 50% growth inhibition). As shown in Table 1, all 2-substituted benzofuranimidazole hybrids lacked activity against the HL-60 and MCF-7 tumor cell lines investigated at a concentration of 40 mg ml21 (except compounds 8 and 24). However, the hybrid compounds were more selective towards ovarian carcinoma cell line (Skov-3).
This journal is The Royal Society of Chemistry 2012

As for Skov-3 cell lines, the structures of the hybrid compounds have an obvious influence on the cytotoxic activities. In terms of the benzofuran ring and imidazole ring, the 2-substituted benzofuran imidazole hybrids 418 with no substituent or a methoxy or an allyl group at the benzofuran ring, as well as with an imidazole ring or alkyl substituted-imidazole ring (methyl or ethyl) were almost inactive (IC50 . 40 mg ml21). However, when a benzimidazole ring was used instead of a imidazole ring, hybrid compounds displayed
RSC Adv., 2012, 2, 46124615 | 4613

View Online

Table 1 Structures and cytotoxic activities of hybrid compounds 424 in vitrob (IC50, mg ml21a) Compound 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 DDP R1 H H H H H OMe OMe OMe OMe H H H H OMe OMe H H H H H H R2 H H H H H H H H H Allyl Allyl Allyl Allyl Allyl Allyl H H H H H H Imidazole ring Imidazole 2-Methyl-imidazole 2-Ethyl-imidazole 4-Methyl-imidazole Benzimidazole Imidazole 2-Methyl-imidazole 2-Ethyl-imidazole Benzimidazole Imidazole 2-Methyl-imidazole 2-Ethyl-imidazole Benzimidazole Imidazole Benzimidazole Imidazole 2-Methyl-imidazole 2-Ethyl-imidazole 2-Ethyl-imidazole 2-Ethyl-imidazole Benzimidazole R4 Benzyl Benzyl Benzyl 2-Bromobenzyl Butyl Benzyl Skov-3 .40 .40 .40 .40 9.5 .40 .40 .40 .40 .40 .40 .40 7.9 36.2 9.3 20.8 25.4 23.2 35.1 39.5 9.1 8.9 HL-60 .40 .40 .40 .40 8.4 .40 .40 .40 .40 .40 .40 .40 .40 .40 .40 .40 .40 .40 .40 .40 7.4 5.5 MCF-7 .40 .40 .40 .40 11.8 .40 .40 .40 .40 .40 .40 .40 .40 .40 .40 .40 .40 .40 .40 .40 12.5 13.0

Downloaded on 13 June 2012 Published on 27 March 2012 on http://pubs.rsc.org | doi:10.1039/C2RA20376F

a Cytotoxicity as IC50 for each cell line, is the concentration of compound which reduced by 50% the optical density of treated cells with respect to untreated cells using the MTT assay. b Data represent the mean values of three independent determinations.

similar cytotoxic activity in vitro compared with DDP (with an IC50 value of 9.5 mg ml21, 7.9 mg ml21 and 9.3 mg ml21 for compounds 8, 16 and 24, except compound 12). Compared with the above hybrid compounds 418, benzofuranbased imidazolium salts 1924 exhibited higher cytotoxic activity. Most of this kind of derivatives showed moderate activity. Similarly, the hybrid salt with a benzimidazole ring (compound 24, with IC50 value of 9.1 mg ml21) exhibited a higher cytotoxic activity than the hybrid salts with an imidazole ring or alkyl substituted-imidazole ring (compounds 1923). Compared with compounds 2123 bearing

the same substituents at position 1 and 2 of the imidazole ring, the cytotoxic activity of the hybrid salt with a benzyl substituent at position 3 of the imidazole ring (R4 group) was higher than that of the hybrid compounds with the other alkyl substituents. The results suggest that 2-substituted benzofuranimidazole hybrids bearing benzimidazole moieties, as well as imidazolium salts at the imidazolyl-3 position with a benzyl group, were vital for modulating cytotoxic activity. The structureactivity relationship (SAR) results were summarized in Scheme 3. In conclusion, a number of novel hybrid compounds between 2-substituted benzofuran and imidazole have been prepared in this research and evaluated in vitro against a panel of human tumor cell lines. The results show that the hybrid compounds were more selective towards ovarian carcinoma cell lines (Skov-3) and suggest that hybrid compounds bearing 2-substituted benzofuran and benzimidazole moieties, as well as imidazolium salts, were vital for modulating cytotoxic activity. The 2-substituted benzofuranimidazole hybrids 24 and 8 can be considered promising leads for further structural modifications guided by the valuable information derivable from our detailed SARs.

Acknowledgements
This work was supported by grants (30960460, 21062026, 2010GA014 and 2009CB522300) from the National Natural Science Foundation of China, Yunnan Province and the National Basic Research Program of China (973 Program).

References
1 H. Varmus, Science, 2006, 312, 1162. 2 C. M. Haskell, in Cancer treatment, W.B. Saunders Company, Philadelphia, PA, 5th edn, 2001, ch. 1. 3 F. Belluti, G. Fontana, L. D. Bo, N. Carenini, C. Giommarelli and F. Zunino, Bioorg. Med. Chem., 2010, 18, 3543. 4 (a) N. T. Patil and Y. Yamamoto, Chem. Rev., 2008, 108, 3395; (b) G. Zeni and R. C. Larock, Chem. Rev., 2006, 106, 4644; (c) X. Jiang, W. Liu, W.

Scheme 3 Structureactivity relationship of hybrid compounds.

4614 | RSC Adv., 2012, 2, 46124615

This journal is The Royal Society of Chemistry 2012

View Online
Zhang, F. Jiang, Z. Gao, H. Zhuang and L. Fu, Eur. J. Med. Chem., 2011, 46, 3526; (d) V. Kuete, D. C. Fozing, W. F. G. D. Kapche, A. T. Mbaveng, J. R. Kuiate, B. T. Ngadjui and B. M. Abegaze, J. Ethnopharmacol., 2009, 124, 551; (e) S. H. Kim, H. S. Pak, M. S. Lee, Y. J. Cho, Y. S. Kim, J. T. Hwang, M. J. Sung, M. S. Kim and D. Y. Kwon, Biochem. Biophys. Res. Commun., 2008, 372, 108; (f) E. M. Wenzig, W. Oleszek, A. Stochmal, O. Kunert and R. Bauer, J. Agric. Food Chem., 2008, 56, 8885; (g) H. Saroyobudiono, L. D. Juliawaty, Y. M. Syah, S. A. Achmad, E. H. Hakim, J. Latip and I. M. Said, J. Nat. Med., 2008, 62, 195; (h) T. Ka lai, G. Va rbiro , Z. Bogna r, A. Pa lfi, K. Hanto , B. Bogna r, E. Osz, B. Su megi and K. Hideg, Bioorg. Med. Chem., 2005, 13, 2629; (i) M. Halabalaki, N. Aligiannis, Z. Papoutsi, S. Mitakou, P. Moutsatsou, C. Sekeris and A.-L. Skaltsounis, J. Nat. Prod., 2000, 63, 1672; (j) S. M. Bakunova, S. A. Bakunov, T. Wenzler, T. Barszcz, K. A. Werbovetz, R. Brun, J. E. Hall and R. R. Tidwell, J. Med. Chem., 2007, 50, 5807. (a) N. T. Dat, X. J. Jin, K. Lee, Y. S. Hong, Y. H. Kim and J. J. Lee, J. Nat. Prod., 2009, 72, 39; (b) E. S. Katsanou, M. Halabalaki, N. Aligiannis, S. Mitakou, A. L. Skaltsounis, X. Alexi, H. Pratsinis and M. N. Alexis, J. Steroid Biochem. Mol. Biol., 2007, 104, 228. S. Van Miert, S. Van Dyck, T. J. Schmidt, R. Brun, A. Vlietinck, G. Lemiere and L. Pieters, Bioorg. Med. Chem., 2005, 13, 661. S. Ganapaty, G. V. K. Srilakshmi, S. T. Pannakal, H. Rahman, H. Laatsch and R. Brun, Phytochemistry, 2009, 70, 95. (a) E. E. Alberto, L. L. Rossato, S. H. Alves, D. Alves and A. L. Braga, Org. Biomol. Chem., 2011, 9, 1001; (b) A. Vik, E. Hedner, C. Charnock, L. W. Tangen, . Samuelsen, R. Larsson, L. Bohlinb and L. L. Gundersen, Bioorg. Med. Chem., 2007, 15, 4016; (c) Q. L. Li, J. Huang, Q. Wang, N. Jiang, C. Q. Xia, H. H. Lin, J. Wua and X. Q. Yu, Bioorg. Med. Chem., 2006, 14, 4151; (d) H. Miyachi, H. Kiyota and M. Segawa, Bioorg. Med. Chem. Lett., 1999, 9, 3003; (e) S. J. Dominianni and T. T. Yen, J. Med. Chem., 1989, 32, 2301; (f) R. Lis, T. K. Morgan Jr., R. J. De Vita, D. D. Davey, W. C. Lumman Jr., R. A. Wohl, J. Diamond, S. S. Wong and M. E. Sullivan, J. Med. Chem., 1987, 30, 696; (g) K. Iizuka, T. Kamijo, R. Yamamoto and H. Harada, US. Patent 4,461,905, 1984; (h) R. D. Haugwitz and V. L. Narayanan, U.S. Patent 3,852,301, 1974. (a) C. G. Fortuna, V. Barresi, G. Berellini and G. Musumarra, Bioorg. Med. Chem., 2008, 16, 4150; (b) F. P. Ballistreri, V. Barresi, P. Benedetti, G. Caltabiano, C. G. Fortuna, M. L. Longo and G. Musumarraa, Bioorg. Med. Chem., 2004, 12, 1689. B. Cui, B. L. Zheng, K. He and Q. Y. Zheng, J. Nat. Prod., 2003, 66, 1101. (a) W. Chen, X. D. Yang, Y. Li, L. J. Yang, X. Q. Wang, G. L. Zhang and H. B. Zhang, Org. Biomol. Chem., 2011, 9, 4250; (b) X. H. Zeng, X. D. Yang, Y. L. Zhang, C. Qing and H. B. Zhang, Bioorg. Med. Chem. Lett., 2010, 20, 1844; (c) X. D. Yang, X. H. Zeng, Y. L. Zhang, C. Qing, W. J. Song, L. Li and H. B. Zhang, Bioorg. Med. Chem. Lett., 2009, 19, 1892. (a) E. M. Guantai, K. Ncokazi, T. J. Egan, J. Gut, P. J. Rosenthal, P. J. Smith and K. Chibale, Bioorg. Med. Chem., 2010, 18, 8243; (b) C. Viegas Jnr, A. Danuello, V. S. Bolzani, E. J. Barreiro and C. A. M. Fraga, Curr. Med. Chem., 2007, 14, 1829; (c) J. J. Walsh and A. Bell, Curr. Pharm. Des., 2009, 15, 2970. 13 S. Pautus, S. W. Yee, M. Jayne, M. P. Coogan and C. Simons, Bioorg. Med. Chem., 2006, 14, 3643. 14 M. Ashram, J. Chem. Soc., Perkin Trans. 2, 2002, 1662. 15 K. A. Korthals and W. D. Wulff, J. Am. Chem. Soc., 2008, 130, 2898. 16 General procedure for the preparation of 2-substituted benzofuran imidazole hybrids 418. To a solution of benzofuran 2-methanol compound 3 (1 mmol) in dichloromethane (50 mL) was added methanesulfonyl chloride (1.2 mmol) and triethylamine (2 mmol) at 0 uC. The resulting mixture was stirred at room temperature for 2 h. After quenching the reaction with water (50 mL), the layers were separated. The organic phase was dried over anhydrous Na2SO4 and concentrated, and used for the next synthetic step. A mixture of the previous methanesulfonate and imidazole or substituted imidazole (3 mmol) was stirred in toluene (20 ml) at reflux for 2448 h (monitored by TLC). After cooling to room temperature, the solvent was concentrated, and the residue was diluted with EtOAc (20 mL). The organic layer was washed with water (20 mL) and brine (20 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by column chromatography (silica gel, petroleum ether 6090 uC, ethyl acetate) to afford 418 in 5483% yield (two steps). Compound 8: white powder, yield 78%, mp 128130uC (CHCl3). 1H NMR (300 MHz, CDCl3) d 7.96 (1H, s), 7.847.81 (1H, m), 7.477.37 (3H, m), 7.287.17 (4H, m), 6.56 (1H, s), 5.32 (2H, s). 13C NMR (75 MHz, CDCl3) d 155.08 (C), 151.07 (C), 143.82 (C), 143.02 (CH), 133.66 (C), 127.69 (C), 124.86 (CH), 123.24 (CH), 122.42 (CH), 121.20 (CH), 120.47 (CH), 111.32 (CH), 109.77 (CH), 105.51 (CH), 42.18 (CH2). HR-ESI-MS m/z Calcd for C16H12N2O 248.0950, Found 248.0944. Anal. Calcd for C16H12N2O: C, 77.40; H, 4.87; N, 11.28. Found: C, 77.33; H, 4.86; N 10.95. 17 General procedure for the preparation of 2-substituted benzofuran imidazolium bromides 1924. A mixture of 2-substituted benzofuran imidazole hybrids 418 (1 mmol) and alkyl bromides (1.2 mmol) was stirred in toluene (10 ml) at reflux for 816 h. A white solid was formed. After completion of the reaction as indicated by TLC, the precipitate was filtered through a small pad of Celite, and washed with toluene (3 6 10 ml), then dried to afford 1924 in 7592% yield. Pure samples were obtained after recrystallization from an appropriate solvent (acetone or methanol). Compound 24: white powder, yield 89%, mp 218220 uC (MeOH). 1H NMR (300 MHz, MeOD) d 8.39 (1H, s), 6.60 (1H, d, J = 7.6 Hz), 6.37 (1H, d, J = 7.6 Hz), 6.196.10 (3H, m), 6.015.91 (6H, m), 5.805.73 (2H, m), 5.70 (s, 1H), 4.52 (s, 2H), 4.27 (s, 2H). 13C NMR (75 MHz, MeOD) d 148.74 (C), 142.01 (C), 133.02 (C), 131.42 (C), 129.04 (CH), 128.91 (CH), 128.04 (CH), 127.57 (C), 127.20 (CH), 127.09 (CH), 125.19 (CH), 123.12 (CH), 121.37 (CH), 113.67 (CH), 113.48 (CH), 110.81 (CH), 107.80 (CH), 50.77 (CH2), 43.86 (CH2). HR-ESI-MS m/z Calcd for C23H19N2O [M-Br]+ 339.1492, Found 339.1483. Anal. Calcd for C23H19BrN2O: C, 65.88; H, 4.57; N, 6.68. Found: C, 66.29; H, 4.57; N 6.31. 18 (a) D.-K. Kim, D. H. Ryu, J. Y. Lee, N. Lee, Y.-W. Kim, J.-S. Kim, K. Chang, G.-J. Im, T.-K. Kim and W.-S. Choi, J. Med. Chem., 2001, 44, 1594; (b) R. Cao, Q. Chen, X. Hou, H. Chen, H. Guan, Y. Ma, W. Peng and A. Xu, Bioorg. Med. Chem., 2004, 12, 4613.

Downloaded on 13 June 2012 Published on 27 March 2012 on http://pubs.rsc.org | doi:10.1039/C2RA20376F

6 7 8

10 11

12

This journal is The Royal Society of Chemistry 2012

RSC Adv., 2012, 2, 46124615 | 4615